Age-Related Disease Risks Up for Younger B-NHL SurvivorsLast Updated: November 04, 2021.
THURSDAY, Nov. 4, 2021 (HealthDay News) -- Younger B-cell non-Hodgkin lymphoma (B-NHL) survivors have increased relative risks for specific age-related diseases (acute renal failure, pneumonia, and nutritional deficiencies) compared with older survivors relative to their peers in the general population, according to a study published online Nov. 1 in Cancer Epidemiology, Biomarkers & Prevention.
Krista Ocier, Ph.D., M.P.H., from the University of Utah School of Medicine in Salt Lake City, and colleagues estimated the incidence of age-related disease beside cardiovascular disease among younger versus older B-NHL survivors compared with general population cohorts. Survivors of B-NHL, diagnosed between 1997 and 2015, were matched with up to five cancer-free individuals on sex, birth year, and state of birth; data were included for 2,129 B-NHL survivors and 8,969 matched individuals.
The researchers found that at five or more years after cancer diagnosis, younger B-NHL survivors (<65 years) had higher relative risks for acute renal failure, pneumonia, and nutritional deficiencies (hazard ratios, 2.24, 2.42, and 2.08, respectively) compared with older survivors (≥65 years) relative to matched individuals.
"Earlier onset of age-related diseases is likely to occur among younger NHL survivors; therefore, periodic screening for a range of health outcomes and standardized care targeting these outcomes may be beneficial," Ocier said in a statement. "Our results also support the possible need for nutritional intervention during and after cancer treatment because nutritional deficiencies may impact the overall quality of life of B-NHL survivors, especially the younger ones, as they age."
One author disclosed financial ties to Backdrop Health, which specialized in analytics using electronic health record data. A second author disclosed receipt of personal fees from McKesson Corporation.
|Previous: Urine Biomarker May Help Determine Prognosis in Prostate Cancer||Next: mRNA COVID-19 Efficacy Lower for Immunocompromised Adults|
Reader comments on this article are listed below. Review our comments policy.